Cargando…

Molecular and clinical characteristics of IDH mutations in Chinese NSCLC patients and potential treatment strategies

BACKGROUND: Isocitrate dehydrogenase (IDH) is an appealing target for anticancer therapy, and IDH (IDH1/2) inhibitors have been approved for targeted therapy of acute myeloid leukemia (AML) and Cholangiocarcinoma. The therapeutic potential of IDH inhibitors for non‐small‐cell lung cancer (NSCLC) pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Shuchen, Zhu, Honglin, Jin, Meizi, Yuan, Hongling, Liu, Zhenzhen, Li, Jielin, Zhang, Xiang, Meng, Lihui, Li, Ting, Diao, Yuzhu, Gao, Hong, Hong, Chengyu, Zhu, Xinjiang, Zheng, Jian, Li, Fei, Niu, Yanling, Ma, Tonghui, Li, Xiaoling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678110/ https://www.ncbi.nlm.nih.gov/pubmed/35526267 http://dx.doi.org/10.1002/cam4.4764

Ejemplares similares

Identification of nine mutant genes and establishment of three prediction models of organ tropism metastases of non‐small cell lung cancer
por: Chen, Shuchen, et al.
Publicado: (2022)

Body mass index and serum markers associated with progression-free survival in lung cancer patients treated with immune checkpoint inhibitors
por: Liu, Zhenzhen, et al.
Publicado: (2022)

Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma
por: Jia, Dong-Dong, et al.
Publicado: (2021)

Genomic and Transcriptional Profiling of Chinese Melanoma Patients Enhanced Potentially Druggable Targets: A Multicenter Study
por: Li, Yue, et al.
Publicado: (2022)

The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas
por: Wang, Hao-Yuan, et al.
Publicado: (2016)

The Frequency and Clinical Significance of IDH1 Mutations in Chinese Acute Myeloid Leukemia Patients
por: Guan, Lixun, et al.
Publicado: (2013)

Association of KMT2C/D loss‐of‐function variants with response to immune checkpoint blockades in colorectal cancer
por: Liu, Ruiqi, et al.
Publicado: (2023)

Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival
por: Wang, Peng-Fei, et al.
Publicado: (2017)

Impact of Chemotherapy Delay on Overall Survival for AML with IDH1/2 Mutations: A Study in Adult Chinese Patients
por: Wang, Jing-Han, et al.
Publicado: (2015)

Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: A real-world study in a Chinese population
por: Peng, Lixiu, et al.
Publicado: (2023)

Inhibition of lncRNA PART1 Chemosensitizes Wild Type but Not KRAS Mutant NSCLC Cells
por: Chen, Shu-Chen, et al.
Publicado: (2020)

Effect of IDH3a on glucose uptake in lung adenocarcinoma: A pilot study based on [(18)F]FDG
por: Du, Bulin, et al.
Publicado: (2019)

Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients
por: Deng, Qinfang, et al.
Publicado: (2018)

Lung microbiome alterations in NSCLC patients
por: Zheng, Leliang, et al.
Publicado: (2021)

IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution
por: Rodriguez, Erika F., et al.
Publicado: (2020)

A meta-analysis of the safety and effectiveness of pemetrexed compared with gefitinib for pre-treated advanced or metastatic NSCLC
por: Lu, Xiaoxin, et al.
Publicado: (2020)

Novel insights into molecular patterns of ROS1 fusions in a large Chinese NSCLC cohort: a multicenter study
por: Zhou, Shengyu, et al.
Publicado: (2023)

MicroRNA 101 Attenuated NSCLC Proliferation through IDH2/HIFα Axis Suppression in the Warburg Effect
por: Han, Le, et al.
Publicado: (2022)

Pembrolizumab Plus Chemotherapy for Chinese Patients With Metastatic Squamous NSCLC in KEYNOTE-407
por: Cheng, Ying, et al.
Publicado: (2021)

Crystal Structure of the Isocitrate Dehydrogenase 2 from Acinetobacter baumannii (AbIDH2) Reveals a Novel Dimeric Structure with Two Monomeric-IDH-Like Subunits
por: Wang, Peng, et al.
Publicado: (2018)

IDH-1(R132H) mutation status in diffuse glioma patients: implications for classification
por: Wang, Peng-fei, et al.
Publicado: (2016)

The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET
por: Liu, Feng-Min, et al.
Publicado: (2021)

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)

Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC
por: Xia, Meng, et al.
Publicado: (2020)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications
por: Zhao, Zhiming, et al.
Publicado: (2023)

Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis
por: Chen, Xiu, et al.
Publicado: (2023)

Discovery of Novel Biomarkers of Therapeutic Responses in Han Chinese Pemetrexed-Based Treated Advanced NSCLC Patients
por: Zhang, Xiaoqing, et al.
Publicado: (2019)

Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH Mutations in Glioblastoma
por: Krell, Daniel, et al.
Publicado: (2011)

Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma()()
por: Sun, Chao, et al.
Publicado: (2020)

Prognostic analysis and nomogram construction for older patients with IDH-wild-type glioblastoma
por: Cao, Wenjun, et al.
Publicado: (2023)

Inhibition of IDH3α Enhanced the Efficacy of Chemoimmunotherapy by Regulating Acidic Tumor Microenvironments
por: Zhang, Lingling, et al.
Publicado: (2023)

Landscape of IDH1/2 mutations in Chinese patients with solid tumors: A pan‐cancer analysis
por: Shen, Dong, et al.
Publicado: (2021)

A new ALK inhibitor overcomes resistance to first‐ and second‐generation inhibitors in NSCLC
por: Lu, Yue, et al.
Publicado: (2021)

Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1(R132H) mutation and may predict better prognosis among glioblastomas without the IDH1 mutation and ATRX loss
por: Cai, Hong-Qing, et al.
Publicado: (2018)

Knockdown of ANXA1 suppresses the biological behavior of human NSCLC cells in vitro
por: FANG, YING, et al.
Publicado: (2016)

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021)

The overall survival benefit in Chinese ALK(+) NSCLC patients received targeted therapies
por: Tian, Guangming, et al.
Publicado: (2022)

Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification
por: Sun, Dantong, et al.
Publicado: (2022)

Pazopanib diminishes non-small cell lung cancer (NSCLC) growth and metastases in vivo
por: Zhao, Honglin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_thpr27rqq3ofr68j7hr61a87p1